Get started
Author

Rongrong Kong

Observed institution: Simcere Pharmaceutical (China)
OpenAlex ID: A5032573617
Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma development
2025 · Xiang Li, Yingting Wu, et al. · Investigational New Drugs · 1
Mutational landscape of intracranial germ cell tumors.
2023 · Jiangong Wang, Tiantian Han, et al. · Journal of Clinical Oncology · 1
PDF
Prevalence and characteristics analysis of CDKN2A/B deletion in glioma.
2023 · Dongxiao Zhuang, Tiantian Han, et al. · Journal of Clinical Oncology · 1
PDF
Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.
2023 · Jianmin Li, Tiantian Han, et al. · Journal of Clinical Oncology · 1
YAP1::MAML2 fusion-positive high-grade neuroepithelial tumors with rhabdoid morphology and inflammatory microenvironment: Implications for integrated diagnosis
2026 · Hainan Li, Xuemin Wei, et al. · Journal of Neuropathology & Experimental Neurology
Hints for reclassification of meningiomas based on the fifth edition of WHO CNS.
2023 · Chuandong Cheng, Tiantian Han, et al. · Journal of Clinical Oncology
Genomic analysis in NF2 meningiomas: Does co-mutation suggest new subgroups?
2023 · Yanfeng Xi, Didi Guo, et al. · Journal of Clinical Oncology
PDF
Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.
2023 · Zhiliang Liu, Tiantian Han, et al. · Journal of Clinical Oncology
A comprehensive analysis of clinical characterization in 149 Chinese patients with Lynch syndrome.
2023 · Junqiong Lin, Rongrong Kong, et al. · Journal of Clinical Oncology
PDF
Works count: 9
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type